Yanan Zhu
Stock Analyst at Wells Fargo
(1.87)
# 3,197
Out of 5,245 analysts
90
Total ratings
35.53%
Success rate
-9.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGX Metagenomi Therapeutics | Maintains: Overweight | $12 → $9 | $1.35 | +566.67% | 5 | May 12, 2026 | |
| ENGN enGene Therapeutics | Downgrades: Equal-Weight | $25 → $2 | $1.64 | +21.95% | 2 | May 8, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $95 → $105 | $76.94 | +36.47% | 2 | May 7, 2026 | |
| ONC BeOne Medicines AG | Initiates: Overweight | $400 | $310.25 | +28.93% | 1 | May 4, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $50 → $90 | $74.05 | +21.54% | 4 | Apr 14, 2026 | |
| RNA Atrium Therapeutics | Initiates: Overweight | $25 | $13.07 | +91.28% | 5 | Mar 11, 2026 | |
| QURE uniQure | Upgrades: Overweight | $15 → $60 | $24.19 | +148.04% | 7 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $12 → $15 | $12.60 | +19.05% | 8 | Mar 3, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $45 → $38 | $16.80 | +126.19% | 8 | Feb 27, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $5.49 | +100.36% | 4 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $100 | $75.56 | +32.35% | 4 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $20 | $7.03 | +184.50% | 9 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $4 | $2.76 | +44.93% | 7 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $35.44 | +26.98% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $2.25 | +11.11% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.70 | +194.12% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $4.11 | +240.63% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $28.64 | +144.41% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.80 | +163.16% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $50.36 | +29.07% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.42 | +18,495.04% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $806.46 | -59.58% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.25 | +582.93% | 2 | Oct 29, 2020 |
Metagenomi Therapeutics
May 12, 2026
Maintains: Overweight
Price Target: $12 → $9
Current: $1.35
Upside: +566.67%
enGene Therapeutics
May 8, 2026
Downgrades: Equal-Weight
Price Target: $25 → $2
Current: $1.64
Upside: +21.95%
Cytokinetics
May 7, 2026
Maintains: Overweight
Price Target: $95 → $105
Current: $76.94
Upside: +36.47%
BeOne Medicines AG
May 4, 2026
Initiates: Overweight
Price Target: $400
Current: $310.25
Upside: +28.93%
Spyre Therapeutics
Apr 14, 2026
Maintains: Overweight
Price Target: $50 → $90
Current: $74.05
Upside: +21.54%
Atrium Therapeutics
Mar 11, 2026
Initiates: Overweight
Price Target: $25
Current: $13.07
Upside: +91.28%
uniQure
Mar 9, 2026
Upgrades: Overweight
Price Target: $15 → $60
Current: $24.19
Upside: +148.04%
Intellia Therapeutics
Mar 3, 2026
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $12.60
Upside: +19.05%
Sarepta Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $45 → $38
Current: $16.80
Upside: +126.19%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $5.49
Upside: +100.36%
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $75.56
Upside: +32.35%
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $7.03
Upside: +184.50%
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.76
Upside: +44.93%
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $35.44
Upside: +26.98%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $2.25
Upside: +11.11%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.70
Upside: +194.12%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $4.11
Upside: +240.63%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $28.64
Upside: +144.41%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.80
Upside: +163.16%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $50.36
Upside: +29.07%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.42
Upside: +18,495.04%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $806.46
Upside: -59.58%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.25
Upside: +582.93%